Browse EX-10 agreements

FORBRIGHT, INC.

2026 OMNIBUS INCENTIVE PLAN

DIRECTOR RESTRICTED STOCK UNIT GRANT NOTICE

Forbright, Inc., a Delaware corporation (the “Company”), pursuant to its 2026 Omnibus Incentive Plan (as may be amended from time to time, the “Plan”), hereby grants [●] (the “Participant”) this award of Restricted Stock Units as set forth below (the “Award”). The Award is subject to all of the terms and conditions as set forth in this Restricted Stock Unit Grant Notice (the “Grant Notice”), the Restricted Stock Unit Award Agreement attached hereto as Exhibit A (the “RSU Award Agreement”), and the Plan, all of which are incorporated herein in their entirety. Capitalized terms not explicitly defined herein but defined in the Plan or the RSU Award Agreement will have the same definitions as in the Plan or the RSU Award Agreement. If there is any conflict between the terms in this Grant Notice and the Plan, the terms of the Plan will control.

Date of Grant: [●]

Number of Restricted Stock Units Granted: [●]

Vesting Terms:

…

FORBRIGHT, INC.

NON-EMPLOYEE DIRECTOR DEFERRED COMPENSATION PLAN

Section 1.						Purpose and Effective Date

The name of the Plan is the Forbright, Inc. Non-Employee Director Deferred Compensation Plan. The purpose of the Plan is to provide the non-employee members of the Board of Directors (the “Board”) of Forbright, Inc., a Delaware corporation (the “Company”), with a means to defer compensation earned as a member of the Board.

The Plan is effective as of the date that the registration statement on Form S-1 that is filed by the Company with respect to its initial public offering covering the offer and sale by the Company of its Common Stock is declared effective by the U.S. Securities and Exchange Commission (the “Effective Date”).

Section 2.						Definitions

…

FORM OF INVESTOR RIGHTS’ AGREEMENT

THIS INVESTOR RIGHTS’ AGREEMENT (this “Agreement”), is made as of [ó], 2026, by and [between][among] Forbright, Inc., a Delaware corporation (the “Company”), and [ó] (the “Investor”) [and, solely for purposes of Section 3, Section 4.5, Section 8 and Section 9 hereof, [ó] (each, an “Affiliate Party”, and collectively, the “Affiliate Parties”)]1.

RECITALS

WHEREAS, the Company and its Affiliates (as defined herein) intend to consummate the transactions described in the Registration Statement on Form S-1 (Registration No. 333-295966) (the “IPO”); and

WHEREAS, the Investor and the Company desire to address herein certain relationships among themselves with respect to the governance of the Company.

NOW, THEREFORE, in consideration of the mutual covenants and understandings defined herein and for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

NOW, THEREFORE, the parties hereby agree as follows:

1.    Definitions. For purposes of this Agreement:

…

THE SECURITIES REPRESENTED BY THIS AGREEMENT HAVE BEEN ACQUIRED

FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES

ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR ANY STATE SECURITIES

LAWS. SUCH SECURITIES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE

OF SUCH REGISTRATION OR AN EXEMPTION THEREFROM UNDER THE

SECURITIES ACT AND ANY APPLICABLE STATE SECURITIES LAWS.

FORBRIGHT, INC.

AWARD AGREEMENT

This Award Agreement (this “Agreement”) is made and entered into this [●] day of [●], [●] (the “Date of Grant”), by and between (i) Forbright, Inc. (f/k/a Congressional Bancshares, Inc., the “Company”) and (ii) [●] (the “Participant”), an employee of Forbright Bank, a wholly owned subsidiary of the Company (the “Bank”).

RECITALS

A.    The Company has adopted the Congressional Bancshares, Inc. 2014 Stock Incentive Plan, as amended (the “Plan”), authorizing the Company to make awards to persons associated with the Company and the Bank (as applicable).

…

PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK

Number of Shares: [ ⚫ ]

(subject to adjustment)

Warrant No. PFW-06-2026-[ ⚫ ]		Original Issue Date: [ ⚫ ]

Eloxx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ⚫ ] or its registered assigns (the “Holder”), is entitled, subject to the terms set forth below, to purchase from the Company up to a total of [ ⚫ ] shares of common stock, $0.01 par value per share (the “Common Stock”), of the Company (each such share, a “Warrant Share” and all such shares, the “Warrant Shares”) at an exercise price per share equal to $0.01 (the “Exercise Price”), in each case as adjusted from time to time as provided in Section 9, upon surrender of this Pre-Funded Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, the

…

Execution Version

REGISTRATION RIGHTS AGREEMENT

THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of August 20, 2025 (the “Effective Date”) is entered into by and among Eloxx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Securities Purchase Agreement by and among the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”).

WHEREAS:

…

Exhibit 10.58

ELOXX PHARMACEUTICALS, INC.

AMENDED AND RESTATED 2018 EQUITY INCENTIVE PLAN

ADOPTED BY THE BOARD OF DIRECTORS: APRIL 28, 2026

APPROVED BY THE STOCKHOLDERS: APRIL 28, 2026

EFFECTIVE DATE: APRIL 28, 2026

1.	GENERAL.

(a) Plan History. The Eloxx Pharmaceuticals, Inc. 2018 Equity Incentive Plan (the “2018 Plan”) was first adopted by the Board on March 12, 2018 and approved by our stockholders on March 26, 2018 (the “Original Effective Date”). On September 19, 2025, it was amended to increase the Share Reserve and aggregate Incentive Stock Option limit. As of the Effective Date, the 2018 Plan was amended and restated (as amended and restated, the “Plan”) to extend the term of the 2018 Plan and to make certain other clarifying and administrative amendments thereto.

(b) Eligible Award Recipients. Employees, Directors and Consultants are eligible to receive Awards.

…

CONSULTING AGREEMENT

This Consulting Agreement (the “Agreement”) is made effective as of April 1, 2021 (the “Effective Date”), by and between Eloxx Pharmaceuticals, Inc., a Delaware corporation, with its principal place of business being 950 Winter Street, Waltham MA 02451 (the “Company”) and Danforth Advisors, LLC, a Massachusetts limited liability company, with its principal place of business being 91 Middle Road, Southborough, MA 01772 (“Danforth”). The Company and Danforth are herein sometimes referred to individually as a “Party” and collectively as the “Parties.”

WHEREAS, the Company is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are formulated to treat rare and ultra-rare premature stop codon diseases; and

WHEREAS, Danforth has expertise in financial and corporate operations and strategy; and

…

Exhibit 10.5

PRIVATE PLACEMENT UNITS PURCHASE AGREEMENT

This PRIVATE PLACEMENT UNITS PURCHASE AGREEMENT (this “Agreement”) is made as of the [●] day of [_], 2026, by and between Innovative Digital Investors Acquisition Corp., a Nevada corporation (the “Company”), having its principal place of business at 104 S. Walnut Street, Unit 1A, Itasca, Illinois 60143, and Innovative Digital Investors, LLC, a Nevada limited liability company (the “Subscriber”), having its principal place of business at 104 S. Walnut Street, Unit 1A, Itasca, Illinois 60143.

…

STOCK CANCELLATION AGREEMENT

This Stock Cancellation Agreement (the “Agreement”) is made effective as of May 30, 2026 (the “Effective Date”), by and among Innovative Digital Investors Acquisition Corp., a Nevada corporation (the “Company”), and the holders of Founder Shares (defined below) signatory hereto (the “Holders” and together with the Company, the “Parties”).

WHEREAS, the Company initially contemplated conducting an initial public offering of $200,000,000 of shares of common stock of the Company, which has been reduced to an initial public offering of $125,000,000 of shares of common stock of the Company (the “IPO”); and

WHEREAS, as a result of the reduction in the size of the IPO, the Company and the Holders intend that the total number of shares issued to founders of the Company (the “Founder Shares”) be reduced from 8,250,000 to 6,095,000, and that the aggregate number of shares issued to the Holders be reduced accordingly, as set forth in Exhibit A hereto (the “Subject Shares”), resulting in the cancellation of 2,155,000 shares of common stock of the Company.

…

Exhibit 10.3

REGISTRATION RIGHTS AGREEMENT

THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of [__], 2026, is made and entered into by and among Innovative Digital Investors Acquisition Corp., a Nevada corporation (the “Company”), Innovative Digital Investors, LLC, a Nevada limited liability company (the “Sponsor”), ThinkEquity LLC, as representatives of the underwriters (the “Underwriters”) and the undersigned parties listed on the signature page hereto under “Holders” (each such party, together with the Sponsor, the Underwriters and any person or entity who hereafter becomes a party to this Agreement pursuant to Section 5.2 of this Agreement, a “Holder” and collectively the “Holders”).

RECITALS

…

Exhibit 10.1

[_], 2026

Innovative Digital Investors Acquisition Corp.

104 S. Walnut Street, Unit 1A

Itasca, Illinois 60143

Re: Initial Public Offering

Ladies and Gentlemen:

This letter (this “Letter Agreement”) is being delivered to you in accordance with the Underwriting Agreement (the “Underwriting Agreement”) entered into by and between Innovative Digital Investors Acquisition Corp., a Nevada corporation (the “Company”), and ThinkEquity LLC, as the representative (the “Representative”) of the several underwriters (each, an “Underwriter” and collectively, the “Underwriters”), relating to an underwritten initial public offering (the “Public Offering”), of up to 14,375,000 of the Company’s units (including up to 1,875,000 units that may be purchased to cover over-allotments, if any) (the “Units”), each comprised of one share of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), and three-quarters of one redeemable warrant. Each whole warrant

…